- A study from the Ella Institute of Melanoma, Ramat-Gan, Israel has reported that “MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth.”
- This study was published in the 3 June 2013 Journal of Clinical Investigations (IF: 15+) by Prof. Markel G, Nemlich Y and others from Ella Institute of Melanoma, Ramat-Gan, Israel.
- On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: Natural product-based therapy for Metastatic Melanoma: Oredontin, a compound isolated from medicinal herbs, increases the expression of RNA-editing enzyme ADAR1(Adenosine Deaminase Acting on RNA) via down regulation of its target gene. This study suggests that Oredontin, by suppressing the expression of its target gene, it could inhibit metastatic melanoma. Together, this study suggests that pharmacological formulations containing “Oredontin” can be used to treat metastatic human tumors such as metastatic melanoma.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Natural product-based therapy for Metastatic Melanoma: Oredontin, a compound isolated from medicinal herbs, increases the expression of RNA-editing enzyme ADAR1 (Adenosine Deaminase Acting on RNA) via down regulation of its target gene, 14/June/2014, 7.45 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
